Connect with us

Business

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Stock Tanks After Release Of Disappointing Result On Safety Profile of Zygel

Published

on

Zynerba Pharmaceuticals (NASDAQ:ZYNE) shares plunged 15% on Wednesday at the back of the announcement of results of the open-label second phase BELIEVE 1 trial. The study is evaluating efficacy and safety of topical cannabinoid Zygel in treating developmental and epileptic encephalopathy. Shared slumped following disappointing results regarding the safety profile of Zygel.

Zynerba CEO says Zygel has a better safety profile

However, CEO Armando Anido has defended the safety profile of Zygel, stating that it has a better safety profile relative to GW Pharmaceuticals’ (NASDAQ: GWPH) epidiolex. In terms of GI tolerability, liver function and drowsiness Zygel is better than Epidiolex while providing the benefit of topical administration. This is better, especially for most patients who find it hard to swallow pills.

Developmental epileptic encephalopathies (DEE) is a rare group of pediatric epilepsy syndromes that include Lennox-Gastau Syndrome and Dravet Syndrome. Children and adolescents with DEE can receive Zygel as a transdermal gel.

Zygel safety and efficacy results

Top-line results from the study indicated 46 patients in the intention to treat population had a more devastating type of seizures. They experienced over 44%mean reductions in seizures from the second month onward using a regular seizure frequency standardized to 28 days.

Around 5% of the patients had more than 55% mean reduction in attacks after six months under Zygel treatment. Zynerba also indicated that 13 out of the 46 patients had a strain of non-focal impaired responsiveness seizures as well as non-convulsive seizure types at baseline. The company noted that the number of individual seizure types in the patients was very same for the company to come up with a definitive conclusion. Therefore further analyses on the same are necessary.

Despite the company indicating that Zygel was well tolerated that was not encouraging enough for investors. Most investors lay their focus on the negative aspects of Zygel rather than the promising efficacy results. The company is planning to complete analysis of data from the study and meet the FDA in the first half of next year to discuss a possible pathway towards approval.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES

Business1 week ago

Stem Holdings Inc (OTCMKTS:STMH) Reports A Growth Of 960% In Q3 2020: Unveils TJGardens Branded Tinctures

Post Views: 307 Stem Holdings Inc (OTCMKTS:STMH) posted an increase of 960% YoY to $6.7 million in Q3 2020. It...

Business2 weeks ago

Indiva Ltd (OTCMKTS:NDVAF) Signs Three Provincial Agreements: Expands Distribution Network To Eight Provinces: Reports A Robust Growth Of 1273.7% In Q2 2020 Revenues

Post Views: 349 Indiva Ltd (OTCMKTS:NDVAF) posted a robust growth of 1273.7% YoY to CAD 2.826 million in revenues in...

Business2 weeks ago

4Front Ventures Corp (OTCMKTS:FFNTF) Receives Approval From CCC For Mission Dispensary and Cultivation Facilities In Worcester: Will Commence Adult-Use Cannabis Sales

Post Views: 318 CCC (Cannabis Control Commission) in Massachusetts approved cultivation and processing facilities and Mission Dispensary of 4Front Ventures...

Business2 weeks ago

Pure Sunfarms, A Joint Venture Of Village Farms International Inc (NASDAQ:VFF), Ships Bottled Oil Products TO British Columbia

Post Views: 439 Pure Sunfarms, which is a Village Farms International Inc (NASDAQ:VFF) JV, commenced shipment of Cannabis 2.0 products...

INDUSTRIAL HEMP2 weeks ago

Health Canada Grants Cannabis 2.0 License To Abba Medix Corp, An Auxiliary Of Canada House Cannabis Group Inc (OTCMKTS:SARSF)

Post Views: 352 Abba Medix Corp., a wholly-owned subsidiary of Canada House Cannabis Group Inc (OTCMKTS:SARSF), received an amended cannabis...

Business2 weeks ago

SugarBud Craft Growers Corp (OTCMKTS:RLLRF) Receives An Amended License From Health Canada To Sell Dried Cannabis Products

Post Views: 398 SugarBud Craft Growers Corp (OTCMKTS:RLLRF) obtained an amended sales license from Health Canada. It allows the company...